# Why Some People Don't Lose Weight on GLP-1 Drugs Like Ozempic
About 10 percent of GLP-1 users experience little to no weight loss despite taking medications like Ozempic and Wegovy, and researchers have now identified why. Scientists discovered that certain individuals have genetic variations that affect how their bodies respond to glucagon-like peptide-1 drugs.
The research points to differences in insulin sensitivity and metabolic pathways. Some people's bodies fail to activate the appetite-suppressing signals that make GLP-1s effective. Instead of reducing hunger and food intake, the medication produces minimal effects in these non-responders.
A key finding involves the GLP-1 receptor itself. Variations in genes controlling this receptor determine whether the drug binds effectively and triggers weight loss signals in the brain. People with certain genetic profiles simply don't experience the same appetite reduction that makes these medications work for others.
Body composition also plays a role. People with higher percentages of visceral fat respond differently to GLP-1 treatment than those with more subcutaneous fat. The medication works differently across different fat distribution patterns.
Additionally, baseline metabolism matters. Individuals with slower resting metabolic rates show diminished responses to GLP-1 drugs. Researchers found that people who already have efficient metabolic processes don't benefit as dramatically from the appetite-suppressing effects.
Understanding non-response helps doctors predict who will benefit most from GLP-1 therapy before starting treatment. Testing for genetic markers could become standard practice. For the 10 percent who don't respond, alternative approaches like higher doses, different medications, or combined therapies might prove more effective.
This research explains why GLP-1s work remarkably well for most people but fail for a notable minority. The answer lies in individual biology, not willpower or medication quality.